Abstract

The immune checkpoint molecule, B7-H3, which belongs to the B7 family, has been shown to be overexpressed in various cancers. Its role in tumors is not well defined, and many studies suggest that it is associated with poor clinical outcomes. The effect of B7-H3 on laryngeal cancer has not been reported. This study investigated the expression of B7-H3 in laryngeal squamous cell carcinoma (LSCC), and its relationship with clinicopathological factors and prognosis of LSCC patients. The gene expression quantification data and clinical data of LSCC retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database were analyzed to determine the diagnostic and prognostic roles of B7-H3. Quantitative real-time polymerase chain reaction (qRT-PCR) was then performed to determine the gene expression level of B7-H3 between LSCC tissues and paired normal adjacent tissues. In addition, TCGA RNA-seq data was analyzed to evaluate the expression level of B7 family genes. Next, the protein expression of B7-H3 and CD8 in LSCC was determined using immunohistochemistry and immunofluorescence. qRT-PCR results showed that the expression level of B7-H3 mRNA was significantly higher in LSCC tissues than in adjacent normal tissues. Similar results were obtained from the TCGA analysis. The expression of B7-H3 was significantly associated with T stage, lymph node metastasis, and pathological tumor node metastasis (TNM) stage, and it was also an independent factor influencing the overall survival time (OS) of patients with LSCC. In addition, B7-H3 was negatively correlated with CD8+T cells. These results show that B7-H3 is upregulated in LSCC. Therefore, B7-H3 may serve as a biomarker of poor prognosis and a promising therapeutic target in LSCC.

Highlights

  • Laryngeal cancer is ranked as the second most prevalent head and neck tumor after lip and oral cavity cancers worldwide [1]

  • To identify the association of B7 family genes with prognosis of laryngeal squamous cell carcinoma (LSCC), the RNA-Seq data of 32 LSCC samples and 7 normal tissues were obtained from the The Cancer Genome Atlas (TCGA) database

  • The results indicated significant upregulation of B7-1, B7-DC, and B7-H3 in LSCC samples compared to normal levels (Figure 1B)

Read more

Summary

Introduction

Laryngeal cancer is ranked as the second most prevalent head and neck tumor after lip and oral cavity cancers worldwide [1]. A previous study reported that the incidence and number of deaths due to laryngeal cancer increased steadily from 1997 to 2017 worldwide [2]. Prognostic Biomarker B7-H3 in LSCC treatment method for advanced laryngeal cancer. This calls for in-depth research to identify new diagnostic biomarkers and therapeutic targets in laryngeal cancer. Recent studies have confirmed that B7-H3 has an immunosuppressive function in several cancers [4, 5], including non-small cell lung cancer [6], breast cancer [7], and other tumors. In these cancers, it affects the prognosis of patients. The role of B7-H3 in laryngeal cancer has not been elucidated

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call